Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Biogen : Needham Starts Biogen at Buy With $400 Price Target

09/23/2021 | 07:16am EDT


ę MT Newswires 2021
All news about BIOGEN INC.
10/26Cortexyme's Alzheimer's treatment fails to meet main goals in study
RE
10/26Eli Lilly Alzheimer's Programs Head in Different Directions
DJ
10/26Lilly kicks off application for Alzheimer's drug U.S. approval
RE
10/26Mizuho Securities Cuts Biogen's Price Target to $270 From $300, Citing Aduhelm Sales Es..
MT
10/22BIOGEN : Canaccord Genuity Adjusts Biogen PT to $390 From $423, Maintains Buy Rating
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
10/21BIOGEN : UBS Adjusts Price Target on Biogen to $406 From $405, Maintains Buy Rating
MT
10/21BIOGEN : Cowen Adjusts Biogen PT to $375 From $450, Maintains Outperform Rating
MT
10/21BIOGEN : JPMorgan Adjusts Biogen's Price Target to $324 From $425, Maintains Neutral Ratin..
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 879 M - -
Net income 2021 1 604 M - -
Net Debt 2021 2 311 M - -
P/E ratio 2021 24,3x
Yield 2021 -
Capitalization 38 185 M 38 185 M -
EV / Sales 2021 3,72x
EV / Sales 2022 3,49x
Nbr of Employees 9 100
Free-Float 85,5%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 259,95 $
Average target price 357,88 $
Spread / Average Target 37,7%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors